Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

372 patients with Kellgren-Lawrence grade I-III knee osteoarthritis (OA) were randomized to either four intra-articular injections of high-molecular-weight (HMW) hyaluronic acid (HA), three intra-articular injections of HMW HA and one control arthrocentesis, or four sessions of control arthrocentesis. The primary outcome was the percentage of patients demonstrating a minimum 20% relative reduction from baseline in WOMAC pain score. Follow-up was conducted at 8, 12, 16, and 22 weeks after the first treatment session. All groups demonstrated a significant improvement from baseline in pain measures, and there were no significant between-group differences in the degree of pain reduction throughout follow-up. The four-injection HA group demonstrated a significantly higher rate of patients demonstrating a minimum reduction of 20% in WOMAC pain at 8 weeks, but not at any subsequent follow-up time points. At no time point did the three-injection HA group demonstrate a significantly higher rate than the control group for the primary outcome. Patients with Kellgren-Lawrence grade I knee OA severity were removed from the primary outcome analysis that was presented, and left group sizes below the a priori sample size calculation.